重组人可溶性补体受体1型SCR15-18片段对心肌缺血再灌注损伤的保护作用

目的探讨重组人可溶性补体受体1型SCR15-18片段（sCR1-SCR15-18）对心肌缺血再灌注的保护作用。方法36只SD大鼠随机分为假手术（SO）组,缺血再灌注（I／R）组和sCR1-SCR15-18（sCR1）保护组。建立急性心肌缺血再灌注模型,结扎冠状动脉前立即注射磷酸盐缓冲液（0.1mL／100g）或sCR1-SCR15-18蛋白（15mg／kg）。测定心肌梗塞面积,血清中乳酸脱氢酶（LDH）和肌酸激酶（CK）,心肌组织髓过氧化物酶（MPO）活性,HE染色观察心肌病理改变和免疫组织化学法检测C3c。结果（1）心肌梗死面积：I／R组为（22．9±3．0）％,sCR1保护组为（16．1±3．3）％（P〈0．05）。（2）血清心肌酶CK（U／L）：I／R组为3400．9±534．9,sCR1保护组为2532．5±597．1（P〈0．05）。LDH（U／L）：I／R组为6572．0±476．3,sCR1保护组为5436．2±611．3（P〈0．05）。（3）心肌组织MPO活性（U／g）：I／R组为1．12±0．13,sCR1保护组为0．81±0．14（P〈0．05）。（4）心肌病理改变：I／R组心肌有断裂、坏死,间质肿胀,出血及中性粒细胞浸润,sCR1保护组心肌的以上病理变化明显较I／R组减轻。（5）与I／R组比sCR1保护组梗死区心肌组织C3c的沉积减少。结论sCR1-SCR15-18蛋白对大鼠急性心肌缺血再灌注损伤具有保护作用。

Protective effects of recombinant SCR15-18 domain of human soluble complement receptor type 1 on myocardial ischemia and reperfusion injury

OBJECTIVE: To investigate the protective effects of recombinant SCR15-18 domain of human soluble complement receptor type 1 (sCR1-SCR-15-18) in rats underwent myocardial ischemia and reperfusion (I/R). METHODS: Sprague-Dawley rats were randomly divided into three groups (n = 12 each group): sham (SO); 30 min ischemia/3h reperfusion (I/R) and I/R plus sCR1-SCR15-18 (15 mg/kg before I/R, sCR1). Serum LDH, CK and cardiac myeloperoxidase (MPO) activity were measured. Infarct size, myocardial histopathological changes and myocardial C3c were also compared among groups. RESULTS: Infarct size (16.1 +/- 3.3)% vs. (22.9 +/- 3.0)%, infarct zone/left ventricular mass, P < 0. 05] and CK (2532.5 +/- 597.1) U/L vs. (3400.9 +/- 534.9) U/L, P < 0. 05] and LDH (5436.2 +/- 611.3) U/L vs. (6572.0 +/- 476.3) U/L, P < 0. 05] as well as MPO activity in infarct zone (0.81 +/- 0.14) U/g vs. (1.12 +/- 0.13) U/g, P < 0.05] were significantly decreased post sCR1 compared to I/R group. sCR1 also significantly attenuated histological myocardial injury and reduced the deposition of C3c in infarct zone. CONCLUSION: sCR1-SCR15-18 protein exerts cardioprotective effects in this rat I/R model.